Background: Critical limb ischemia (CLI) is a life-and limb-threatening condition affecting 1% to 10% of the population with peripheral arterial disease. Traditional revascularization options are not possible for up to 50% of CLI patients, in which case, the use of cellular therapies, such as bone marrow-derived mesenchymal stem cells (MSCs), hold great promise as an alternative revascularization therapy. However, no randomized, controlled phase 3 trials to date have demonstrated an improvement in limb salvage with cellular therapies. This may be due to poor cell quality (ie, inability to generate a sufficient number of angiogenic MSCs) or to the inadequate retention and viability of MSCs after delivery, or both. Because concerns remain about the expansion and angiogenic potential of autologous MSCs in the CLI population, the objective of this study was to examine the effect of our novel culture media supplement, pooled human platelet lysate (PL), in lieu of the standard fetal bovine serum (FBS), to improve the expansion potential of MSCs from CLI patients. We also characterized the in vitro angiogenic activity of MSCs from the tibia of amputated CLI limbs compared with MSCs from healthy donors. Methods: MSCs were obtained from the tibia of four CLI patients (ISC) and four ISC patients with diabetes mellitus (ISCDDM) undergoing major amputation. Healthy MSCs were aspirated from the iliac crest of four young and healthy donors. MSCs were isolated and expanded in culture with PL or FBS. MSCs from passage 3 to 6 were used for phenotypic marker expression and for adipogenic and osteogenic differentiation and were tested for their in vitro angiogenic activity on human microdermal endothelial cells. In parallel MSCs were cultured to passage 11 for population-doubling calculations. Results: MSCs from ISC and ISCDDM patients and from healthy patients exhibited appropriate expression of cell surface markers and differentiation capacity. Population doublings were significantly greater for PL-stimulated compared with FBSstimulated MSCs in all groups. Biologically active amounts of angiogens were identified in the secretome of all MSCs without consistent trends among groups. PL expansion did not adversely affect the angiogenic activity of MSCs compared with FBS. The ISC and ISCDDM MSCs demonstrated angiogenic effects on endothelial cells similar to those of healthy and ISC MSCs. Conclusions: PL promotes the rapid expansion of MSCs from CLI and healthy persons. Importantly, MSCs expanded from CLI patients demonstrate the desired angiogenic activity compared with their healthy counterparts. We conclude that autologous MSCs from CLI patients can be sufficiently expanded with PL and be expected to deliver requisite angiogenic effects in vivo. We expect the improved expansion of ISC and ISCDDM with PL to be helpful in improving the successful delivery of autologous MSCs to patients with CLI. (J Vasc Surg 2017;65:826-38.) 
Clinical Relevance: Despite the widely held belief that mesenchymal stem cells (MSCs) from patients with multiple vascular comorbidities (eg, diabetes, aged patient) are inferior in quality compared with MSCs from healthy patients, we demonstrate that MSCs from patients with critical limb ischemia have similar angiogenic function in vitro to that of healthy patients and that platelet lysate supplementation of culture media improves the expansion potential of these MSCs. These findings support the use of autologous MSCs to promote angiogenesis and our novel MSC expansion protocol for increasing the number of suitable MSCs from patients with critical limb ischemia for cellular therapy.
Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). CLI patients have inadequate perfusion, leading to rest pain, tissue loss, and amputation rates of w30% at 1 year. 1 Given the increasing incidence of PAD worldwide, 2 the proportion of the population aged >70 years, and the longevity of cardiovascular patients, CLI is likely to increase substantially in the future. 3 Because many patients with CLI do not have appropriate anatomy or conduits for traditional revascularization, 4 ,5 major amputation, with its significant morbidity and 30-day mortality rate, 6 can be the only definitive treatment option. Thus, novel treatments for CLI, such as cellular therapy, are critically needed. 7 Cellular therapies are a promising technology that may be capable of improving limb salvage by preventing major amputation in CLI patients. 8 Mesenchymal stem cells (MSCs) are particularly well suited for CLI because they promote angiogenesis and arteriogenesis through stromal and paracrine activity. 9, 10 To date, several early-phase clinical trials of MSC therapies have shown benefit, 8, 11 but there have been no phase 3 studies demonstrating improved limb salvage (ie, decreased amputation rate) in CLI patients. 8 This has led to a call for deliberate testing and optimization of protocols, including MSC sourcing and expansion protocols. 12 Despite the robust capacity of in vitro testing of MSC quality and expansion, there is an imbalance in the number of bench studies of human MSCs in CLI compared with that of small clinical series. 13 Spurred by the inability to limit amputation rates in recent phase 3 , we believe further investigation into MSC quality and expansion protocols using clinically relevant MSCs is warranted (ie, moving from the bedside to the bench). In the study reported here, we used our access to MSCs from amputated limbs of CLI patients, as a readily available and clinically relevant human source of MSCs, to test their expansion and angiogenic capacity.
To improve the expansion capacity of MSCs in CLI patients, we have generated and validated a MSC manufacturing process that uses pooled human platelet lysate (PL) as a human serum supplement to stimulate rapid MSC expansion. PL avoids the xenogeneic effect of fetal bovine serum (FBS) on MSCs, which can even result in the host rejecting autologous cells. 15 PL is generated following rigorous testing for contamination by the American Red Cross. Most importantly, we already have approval to use PL in a current MSC human trial (IND14825; NCT 01659762). Finally, because PL has been used to salvage MSCs from less robust cell sources, 16 it may provide an advantage to the expansion of MSCs in CLI patients.
Similarly, autologous sourcing of MSCs expanded in human PL may be favored over allogeneic sourcing due to decreased concern for immunogenic rejection in CLI 17 and with repeat dosing. However, there has been a persistent concern in the field of cellular therapy that autologous sourcing of cells in patients with cardiovascular disease may not provide the desired angiogenic effects. Heeschen et al 18 first demonstrated this discrepancy using bone marrow-derived mononuclear cells (MNCs) from patients with chronic ischemic cardiomyopathy. This work led investigators to focus on the MSC component of the bone marrow MNCs, 19 which are more angiogenic, 20 but Neef et al 21 have recently demonstrated impaired quality of MSCs harvested from the sternum of coronary artery bypass grafting patients. Interestingly other investigators have not found these deficits in dialysis patients 22 and other cardiovascular patients. 23 This is thus a topic of intense debate and experimental equipoise requiring greater investigation.
In this study, we used human MSCs from amputated limbs of CLI patients to test the hypotheses that PL promotes a more rapid expansion of MSCs than FBS and that autologous MSCs cultured from patients with CLI stimulate angiogenesis in vitro in a comparable fashion to that of MSCs from healthy donors. Our long-term aim is to develop improved pathways for cell expansion that enable expedited use of autologous MSCs from patients with CLI by using PL as a novel, human-based, blood product source.
METHODS
Cell harvest and culture. After Investigational Review Board approval and informed consent, healthy MSCs were isolated from 10 to 20 mL bone marrow aspirated from the iliac crest of four (three men, one woman) young healthy volunteer donors. Bone marrow aspirates were diluted 1:2 with phosphate-buffered saline (PBS) and layered by a Ficoll density gradient. The cells were centrifuged at 400g for 20 minutes, and thereafter, the MNCs were plated in complete human MSC medium (a-minimum essential medium [MEM; Corning Life Sciences, Lowell, Mass], 10% human platelet lysate [PL] or 10% FBS, 100 U/mL penicillin/streptomycin) at 100,000 to 300,000 cells/cm 2 . Nonadherent hematopoietic cells were removed by changing the medium after 3 days of culture. MSCs were allowed to expand for 7 to 12 days; thereafter, the cells were passaged and reseeded in fresh MSC medium at 1000 cells/cm 2 . Ischemic (ISC) MSCs were harvested from the marrow of transected tibia after patient consent under an Investigational Review Board-approved protocol at Emory University Hospital. The transected bones were brought to the Four persons were included in each group. Groups were labeled as healthy, ISC, or ISCþDM. Bone marrow from healthy donors was harvested from the iliac crest. Bone marrow from ISC and ISCþDM donors was harvested from their tibia after major amputation. Ages, sex, comorbidities, and smoking status are included. Of note, only 2 of 12 patients were active smokers at time of harvest, and both were in the ISC group. Here we show robust proliferation at passage 4, but the ischemic (ISC) and ISC plus diabetes mellitus (ISCþDM) demonstrate decreased confluence at passage 11 (original magnification 10Â). b, Mean population doublings within each passage were then compared between groups (Healthy, ISC, ISC þDM) and media supplement (FBS and PL). Here there are a number of differences that support the benefit of PL over FBS within and between groups at most passages, and the superiority of healthy over ISC and ISC þ DM at later passages, regardless of media supplement. c, When grouping all MSCs by media supplement (FBS vs PL), the benefit of PL over FBS within passages 4, 6-8 is demonstrated. The range bars indicate the standard deviation. *P < .05; **P < .0005. laboratory and cultured under the above conditions. PL was provided by the Emory Personalized Immunotherapy Center. Raw marrow was collected from the tibias, and cells were disaggregated and strained through a 30-mm nylon mesh with a-MEM. Marrow volumes were calculated by volumetric measurement of water in the bone sections used and ranged from 2 to 6 mL among patients. Cells were centrifuged, pelleted, and resuspended in culture. Nonadherent cells were discarded after 48 hours, and fresh media was added. Cells were passaged and reseeded as above.
Population doubling and differentiation assays. MSCs from healthy, ISC donors, or donors with ISC and diabetes mellitus (ISCþDM) were plated at 1000 MSCs/cm 2 and serially passaged with 5% PL or 5% FBS. Total cell count was recorded every 7 days, and population-doubling times were calculated by dividing the number of days over which the cells were allowed cells to grow (7 days) by the doubling time calculated as published. 16 Cumulative population doublings were determined by the sum of populations up to and including each week, which was synonymous with passage number (week 4 ¼ passage 4).
Colony forming units (CFU) were performed as described. 24 Briefly, MSCs were serially diluted in cell culture medium to obtain 100 cells/10 mL of media and plated in triplicate on a 100-mm tissue culture dish (Falcon; Corning Incorporated, Corning, NY). After 10 days, the colonies were fixed with methanol and stained with 0.5% crystal violet solution (Sigma-Aldrich, St. Louis, Mo). The dishes were placed on a grid, and visible colonies were counted by a blinded observer.
Adipogenic differentiation. MSCs were cultured in a-MEM media supplemented with 20% FBS, 100 U/mL penicillin/100 mg/mL streptomycin, 2 mM L-glutamine, 5 mg/mL insulin, 50 mM indomethacin, 1 Â 10
À6
M dexamethasone, and 0.5 mM 3-isobutyl-1-methylxanthine. After 3 weeks, MSCs were fixed and stained with 1.5% w/v Oil Red O for quantification. Osteogenic differentiation. MSCs were cultured in a-MEM media supplemented with 20% FBS, 100 U/mL penicillin/100 mg/mL streptomycin, 2 mM L-glutamine, 6 mM b-glycerol phosphate, 50 ng/mL thyroxine, 1 nM dexamethasone, and 0.5 mM ascorbate 2-phosphate.
After 3 weeks, MSCs were fixed and stained with 0.4 mM Alizarin red for quantification. Fluorescence activated cell sorting profiles of MSCs. Passage 3 MSCs were cultured for 7 days in 5% FBS media or 5% PL in standard media, harvested, resuspended at a concentration of 1 Â 10 6 cells/mL, and analyzed by flow cytometry for the expression of cluster of differentiation (CD) 45, CD34, CD44, CD73, CD90, CD105, and human leukocyte antigen (HLA)-I (BD Biosciences, San Jose, Calif). All samples were run on a Canto II (BD Biosciences) flow cytometry with the appropriate isotype controls. Data are presented as fold change (total mean fluorescent intensity of marker/mean fluorescent intensity) of the marker and isotype. Similarly, all MSCs from each group were grown out to passage 8 in FBS, and fluorescence activated cell sorting analysis was performed again to demonstrate retention of MSC markers.
Secretome. MSC secretion profiles were determined by plating MSCs (passage 4-5) on to six-well plates at a density of 200,000 cells/well for each donor and PL or FBS media condition (n ¼ 4). To maintain concurrent sampling of the secretome and account for the more rapid proliferation of PL-treated cells, MSCs were cultured in 2% PL or 10% FBS. After 24 hours of seeding, culture media was removed from each well, and wells were washed with 2 mL PBS and replaced with 2 mL serum-free media with 0.2% human serum albumin. After 1 hour, media was removed and a fresh 2 mL serum-free media with 0.2% human serum albumin was placed on each well for 24 hours. Secretion of angiogenic factors in MSC-conditioned media (CM) was determined by enzyme-linked immunosorbent assay according to the manufacturer's instructions for basic Fig 2. a, There is a significant increase in the cumulative mesenchymal stem cell (MSC) population doubling for healthy versus ischemic (ISC) and ISC plus diabetes mellitus (ISCþDM) groups beginning at week (and passage) 9 in the fetal bovine serum (FBS) media. b, Similarly cumulative population doubling in healthy donor MSCs were significantly increased over ISC þ DM MSCs in platelet lysate (PL) media beginning at week (and passage) 8. By week (and passage) 10, healthy MSCs' cumulative population doubling was also significantly increased over the ISC MSCs. c-e, When comparing media supplement (FBS vs PL) within each group, all groups demonstrate a significant increase with PL in cumulative population doubling by week (and passage) 8. Of note, the duration (weeks) were chosen by design and passaging for expansion in culture can be sped up to obtain multiple passages in a single week. The range bars indicate the standard deviation. *P < .005; **P < .0005. fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), monocyte chemotactic protein-1 (MCP-1), and vascular endothelial growth factor (VEGF; R&D Systems, Minneapolis, Minn). Statistical analyses were performed using Prism software (GraphPad, San Diego, Calif).
MSC stimulation of endothelial cell invasion, proliferation, and migration. We determined the angiogenic effect of MSCs on endothelial cells (EC) in threedimensional (3-D) assay by adapting our 3-D in vitro cell invasion assay 25 by creating single multicellular cell aggregates of healthy, ISC, and ISCþDM MSCs, which were used with microdermal ECs or ECs alone to form the aggregate pellet. MSCs were labeled red with PKH-26 (Sigma-Aldrich), and ECs were labeled green with PKH-67 (Sigma-Aldrich) before being pelleted in cellulose overnight to form a single-cell pellet. The invading cells were imaged by light (bright field) and fluorescence microscopy (for PKH-labeled cells). The invasion area was semiautomated segmented and defined as the difference between the total invasion area and normalized to the pellet area.
To compare the effect of FBS and PL on MSC invasion and MSC angiogenic effect on ECs, ECs were labeled with PKH-26 (Sigma-Aldrich) before co-culture aggregation. Here we quantified invasion by sprout length using MATLAB, a semiautomated program (The MathWorks, Natick, Mass), and variability in pellet size was accounted for by normalizing sprout length to pellet diameter. Each experiment was performed with six replicates, and the experiments were performed in triplicate. Comparisons were made between healthy, ISC, and ISCþDM MSCs in a blinded fashion over passages 3 to 5.
EC proliferation. ECs were cultured under standard conditions to 80% confluence, serum starved for 24 hours, and then stimulated with MSC-CM from the various MSCs (healthy, ISC, ISCþDM). Positive control cells were stimulated with endothelial cell complete media, and PBS was added for a negative control. Cell growth was quantified (4 wells/time/analysis) after 24 to 48 hours by CellTiter 96 Aqueous reagent (Promega, Madison, Wisc) and quantified by absorbance in a microplate reader. Results were performed in triplicate and analyzed in a blinded fashion.
EC chemotaxis. A Boyden chamber was modified by coating the upper surface of the membrane with fibronectin before seeding of ECs. The lower chamber was replaced with the above CM. Relative EC chemotaxis was quantified as described. 26 The positive control was complete media and the negative control was PBS. Results were obtained in triplicate and analyzed in a blinded fashion.
Statistical analysis. Planned comparisons were analyzed with Student paired t-tests. The Welch correction was used when variances between groups were unequal. Comparisons between multiple groups were normalized and then analyzed with analysis of variance. An a level of .05 was used to determine significance between groups. Donor and media type were analyzed using Tukey post hoc on a repeated-measures two-way analysis of variance at a 95% confidence interval. 
RESULTS

Expansion of MSCs in PL and FBS.
MSCs were cultured from the iliac crest of healthy donors or from the tibia of amputated limbs of ISC and ISCþDM patients ( Table I) .
The efficiency of MSC isolation from healthy volunteers was calculated by comparing the initial seeding of MNCs with the number of MSCs recovered at passage 1. Based on 20 isolations of bone marrow-derived MSCs from healthy donors, a recovery of one MSC requires plating 16.68 6 2.92 MNCs over 9.5 6 1.98 days. Thus, from bone marrow volumes of 10 to 20 mL, we acquire >20 million MSCs at the time of first passage.
CLI MSCs were cultured from marrow volumes ranging from 2 to 6 mL (ISC averaged 4.75 mL; ISCþDM averaged 3.5 mL). Calculating the efficiency of MSC isolation was not possible because MSCs were sorted by adhesion in tissue culture and not preselected by a Ficoll gradient. However, CFUs between all MSCs were similar between healthy and ISC MSC groups ( Supplementary  Fig 1, online only) .
MSC proliferation was robust in all groups at early passages but declined in the ISC and ISCþDM groups in later passages (Fig 1, a) . PL significantly increased population doublings at multiple time points over that of FBS (Fig 1,  b) . PL demonstrated significant benefit over FBS when grouping all MSCs (healthy, ISC, and ISCþDM) and comparing mean population doublings (Fig 1, c) . With serial passaging, there was a gradual stagnation of cumulative population doublings in the ISC and ISC þDM groups as segregated for FBS (Fig 2, a) and PL-treated MSCs (Fig 2, b) . Importantly, PL culture significantly increased the cumulative population doublings over FBS treatment in all groups from week 8 onwards (Fig 2, c- MSC differentiation and cell markers. All MSCs retained their ability to differentiate when cultured in adipogenic and osteogenic media (Fig 3) , and MSCs at passage 3 retained typical MSC markers by flow cytometry analysis without differences between MSCs cultured in FBS and PL (Fig 4) . Similarly, all MSCs from each group were expanded out to passage 8 in FBS, and fluorescence activated cell sorting analysis demonstrated retention of MSC surface markers.
MSC secretome analyses. To determine the angiogenic factor secretion profiles of MSCs, CM from MSCs was collected after 24 hours under serum-free conditions and quantified via enzyme-linked immunosorbent assay. All MSCs secreted detectable levels of the angiogens and chemokines examined (bFGF, HGF, MCP-1, and VEGF) from both PL and FBS media conditions. No significance differences were detected between either donor group or serum supplementation (FBS vs PL) in the secretion of HGF or VEGF, but wide variability was found in the MSC secretion of these angiogens among donors. Significance differences were detected in MCP-1 between FBS and PL in the healthy donors (P < .01), and ISCþDM MSCs secreted significantly more bFGF than healthy donors under PL serum supplementation (Fig 5) .
MSC invasion and stromal support for EC ingrowth. MSCs significantly increased EC invasion area over EC alone pellets at days 2 and 3. Differentially stained MSCs (red) and ECs (green) were used to define the cellular interaction and quantify 3-D invasion of respective cells in this assay (Supplementary Fig 2, a-c, online only) .
We then tested for differences in MSC invasion by bright field and EC invasion by fluorescent imaging (red PKH) between PL and FBS with the same 3-D assay (Fig 6, a and b) . Here, PL culture of MSCs did not have an overt advantage over FBS. However, invasion of ISC MSCs cultured in FBS was decreased compared with FBS and PL-stimulated healthy donor and ISCþDM MSCs (Fig 6, c) . For MSC stimulation of EC invasion, there was increased EC ingrowth when ECs were co-cultured with ISC MSCs cultured in PL compared with healthy MSCs cultured in FBS and compared with ISCþDM MSCs cultured in FBS or PL (Fig 6, d) .
CM from all MSC groups was able to stimulate EC proliferation over that of the negative control (PBS); this was not influenced by PL vs FBS (Fig 7, a) . Similarly the CM from all MSC groups, except healthy MSCs in PL, stimulated increased EC migration compared with the negative control (PBS ; Fig 7, b) . Of note, the CM was far inferior to that of complete endothelial cell medium (human endothelial cell media; Genlantis, San Diego, Calif) in stimulating EC proliferation and migration.
DISCUSSION
This is the first report of in vitro testing of the expansion potential and angiogenic potency of bone marrow MSCs from amputated CLI limbs. We have identified that: (1) PL increased the expansion potential of all MSCs compared with standard FBS; (2) the expansion of MSCs from CLI patients, even at modest yields of w5 per million cells reported in cardiovascular patients, 21 would expanded in PL 500,000-fold for ISCþDM and 2 million-fold for ISC, providing sufficient numbers for clinical use; and (3) we did not identify any obvious limitations to autologous MSC sourcing from CLI patients in this study because MSCs from both CLI patient groups had a similar secretome and angiogenic activity compared with that of healthy MSCs.
Although the tibia will not replace the iliac crest as a marrow harvest site, it could be a source of MSCs for assisting in secondary healing of amputation wounds or for storage for future use in other tissue beds. Here we expanded the MSCs for this work using relatively small volumes of tibia marrow (2-6 mL). In the iliac crest, where larger volumes (Â10) are harvested, an even greater MSC yield would be expected. Finally, the similarities between healthy iliac crest MSCs and CLI tibia MSCs in this study provide proof of concept that amputated limbs are a suitable source of human MSCs for translational experimentation. This is important because human MSCs have many differences in cell markers and function compared with murine and . Results are shown from each patient from samples collected from passages 4 and 5 of MSCs that were isolated and expanded in fetal bovine serum (FBS; circles) or platelet lysate (PL; squares) media supplement. All MSCs had media removed and were maintained in 0.5% human serum albumin for 24 hours before media collection for secretome analysis. Mean of donors is shown by black bar.*P < .05. Although significant increases were identified in bFGF concentrations between healthy and ISCþDM MSCs cultured in PL and in MCP-1 in healthy MSCs cultured in PL, no clear trends were identified demonstrating a superiority or inferiority between cell groups or serum supplement as it relates to the secretome. rodent MSCs that can complicate translation of murine findings to the bedside. 27, 28 Further, we recognize that the environment and MSC quality could be different between the tibia and iliac crest, but to date, the lone report was performed in patients with rheumatoid arthritis, where the authors linked a relative decrease in CFUs in the tibia to a possible deficit in osteogenic differentiation. 29 Although such an investigation in CLI would have merit, our approach is desirable because it allows patients to donate tissue for research that would otherwise be discarded without adding a subsequent and painful procedure or additional surgeon time. The promising results of PL and the desired angiogenic activity of MSCs from the tibia of patients with CLI provides motivation to address remaining concerns before testing this approach clinically. First, the effect of CLI on the quality of the MSC at harvest and the effect of hypoxia on MSC expansion was not evaluated. Although MSCs in bone marrow can live normally under a low oxygen tension (w0%-6%) 30, 31 and MSC expansion is augmented by relative hypoxia, 32,33 a recent publication by Gremmels et al 34 suggests that hypoxia did not play a significant or discriminating role in the CM of healthy and ISC MSCs.
Secondly, we segregated MSCs from CLI patients into ISC and ISCþDM. This even split of CLI patients with ISC and ISCþDM is representative of the CLI population undergoing amputation at our institution and our future target patients.
Next, our sample size (n ¼ 4 per group), although consistent with other studies, 35 is small and may not have been large enough to identify subtle differences between groups. However, given the significant patient-to-patient variability and reproducibility of our results across groups, we are confident that autologous MSCs from ISC and ISCþDM patients can be expanded with PL to sufficient number and expected to provide the desired angiogenic activity. Excitingly, although we kept this focus in this initial work, two recent reports on MSCs from CLI patients (albeit with sample sizes of 11 and 12 patients in the ISC and healthy groups) have demonstrated in vivo angiogenesis in mouse models that was equivalent to that of healthy donors. 34, 36 The similarities between these publications and our work certainly lessen the potential concern about the transferability of our results using MSCs from the tibia to that expected clinically from the iliac crest.
Changes may also have occurred in the MSCs during transection of the bone during amputation that were not controlled for in this study; here, it would be expected that any disturbance of MSCs at harvest would lessen with serial passaging. Also, although our study did attempt to represent both sexes in the ISC (2 male and 2 female patients), ISCþDM (2 male and 2 female patients), and healthy (3 males and 1 female patient) groups, this work was not designed to add to the building body of literature on the role of gender on MSC function. 37 , 38 
CONCLUSIONS
We demonstrate that PL expansion of MSCs from the tibia of CLI patients is superior to that of FBS and that ischemic MSCs have suitable expansion profiles and similar in vitro angiogenic capacity on human microdermal ECs compared with healthy MSCs. Excitingly, the correlation between these findings and that of the existing literature supports the use of marrow from amputated limbs as a clinically relevant source of MSCs for translational investigation. This intentional step from bedside to bench may be useful in improving the likelihood of clinical translation of cellular therapies in patients with CLI through novel investigative new drug applications.
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